New York, NY (PRWEB) December 20, 2013
The medication safety advocates at DrugNews.net are announcing updated information for patients and parents of those who have taken the antipsychotic drug Risperdal.
Patients alleging the drug caused abnormal breast growth have asked a judge to unseal data from Risperdal clinical studies, claiming the information is of high public importance, according to court documents*.
DrugNews is a free resource center providing the latest safety alerts, recalls, studies and legal news to those taking popular prescription drugs.
Risperdal is an atypical antipsychotic drug approved to treat schizophrenia, bipolar disorder and autism in adults. However, Johnson & Johnson and subsidiary Janssen recently paid $2.2 billion in fines and pled guilty to promoting it for unapproved uses, such as treating ADHD in children**.
DrugNews has added studies linking the drug to gynecomastia, or abnormal breast growth that can be accompanied by milk production***. A recent study also found antipsychotic drugs like Abilify, Risperdal, Seroquel and Zyprexa may triple the risk of type-2 diabetes in children****.
Parents have already filed lawsuits alleging Risperdal caused abnormal breast growth in children, leading to settlements by Johnson & Johnson/Janssen*****.
Anyone affected by abnormal breast growth or diabetes after taking Risperdal is urged to visit DrugNews.net or speak with a lawyer about their legal options. Due to the specialized nature of these cases, DrugNews only recommends lawyers who have already handled Risperdal lawsuits.
Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Risperdal and other antipsychotic drugs, or to speak with a lawyer.
*In re: Risperdal Litigation; Case No. 100300296, (Philadelphia Court of Common Pleas, Pennsylvania.)
**DOJ, 11/4/13; U.S. v. Janssen Pharmaceuticals, Inc. (U.S. Dist. Ct. Eastern Pennsylvania), justice.gov/opa/documents/jj/janssen-info.pdf; Reuters, 11/4/13; reuters.com/article/2013/11/04/us-jnj-settlement-idUSBRE9A30MM20131104
***Cedars-Sinai Division of Endocrinology, Sept. 2012; ncbi.nlm.nih.gov/pubmed/22862307
****Vanderbilt University Medical Center, 8/22/13; news.vanderbilt.edu/2013/08/antipsychotic-drug-use-in-children-for-moodbehavior-disorders-increases-type-2-diabetes-risk/
*****Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January Term 2010, No. 00618; Bloomberg, 9/10/12; bloomberg.com/news/2012-09-10/j-j-settles-risperdal-lawsuit-on-opening-day-of-trial.html;